Outcomes of antifungal prophylaxis in high-risk liver transplant recipients - Hadley, S.; Huckabee, C.; Pappas, P.G.; Daly, J.; Rabkin, J.; Kauffman, C.A.; Merion, R.M.; Karchmer, A.W. (Transplant infectious disease, 2009)
Keywords: Adult; Amphotericin B - adverse effects; Amphotericin B - therapeutic use; Antibiotic Prophylaxis; antifungal; Antifungal Agents - adverse effects; Antifungal Agents - therapeutic use; Candida; Candida - classification; Candida - isolation & purification; Candidiasis - epidemiology; Candidiasis - microbiology; Candidiasis - mortality; Candidiasis - prevention & control; Cryptococcosis - epidemiology; Cryptococcosis - microbiology; Cryptococcosis - mortality; Cryptococcosis - prevention & control; Cryptococcus neoformans; Cryptococcus neoformans - isolation & purification; Double-Blind Method; Female; fluconazole; fungal infections; Humans; Incidence; liposomal amphotericin B; liver transplantation; Liver Transplantation - adverse effects; Male; Middle Aged; Mycoses - epidemiology; Mycoses - microbiology; Mycoses - mortality; Mycoses - prevention & control; prophylaxis; Treatment Outcome